

**Sun Pharmaceutical Industries Ltd.**

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai - 400 063, Maharashtra, INDIA.  
Tel. : (91-22) 4324 4324  
Fax : (91-22) 4324 4343  
Website : www.sunpharma.com  
CIN : L24230GJ1993PLC019050



**January 11, 2019**

National Stock Exchange of India Ltd,  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East),  
Mumbai – 400 051.

BSE Limited.,  
Market Operations Dept.  
P. J. Towers,  
Dalal Street,  
Mumbai - 400 001.  
**BSE Code– 524715**

**NSE Code – SUNPHARMA**

Dear Sirs,

**Sub: Updates**

We refer to our press release dated September 14, 2018 regarding “Sun Pharma and SPARC Announce US FDA Approval of XELPROS™ to Treat Open-angle Glaucoma or Ocular Hypertension”.

Further to the above, we wish to inform you that Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) has commercialised XELPROS™ (Latanoprost ophthalmic emulsion) 0.005%, in US.

The Company had in-licensed XELPROS™ from Sun Pharma Advanced Research Company Limited (“SPARC”) in June 2015 and this commercialization of XELPROS™, has triggered a milestone payment of USD 10 Million and sales linked royalties, by the Company to SPARC.

This is for your information and record.

Thanking you,

Yours faithfully,

**For Sun Pharmaceutical Industries Ltd.,**

**Ashok Bhuta**

**Compliance Officer**